Literature DB >> 3094444

In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.

N Manek, J M Andrews, R Wise.   

Abstract

Ro 23-6240 is a new difluorinated quinolone antimicrobial agent. Its in vitro activity against a wide range of bacteria was compared with those of other quinolones and beta-lactams. Generally, members of the family Enterobacteriaceae were inhibited by low concentrations of Ro 23-6240 (MIC90 [MIC for 90% of isolates tested], less than or equal to 1 microgram/ml). Ninety percent of Staphylococcus aureus (including methicillin-resistant strains) and Neisseria gonorrhoeae isolates were inhibited by 0.5 microgram/ml. Pseudomonas aeruginosa (MIC90, 2 micrograms/ml) and Bacteroides fragilis (MIC90, 4 micrograms/ml) showed intermediate susceptibility, and Streptococcus pneumoniae (MIC90, 8 micrograms/ml) was less susceptible. Strains resistant to nalidixic acid were less susceptible to all the quinolones tested. The protein binding of Ro 23-6240 (5 micrograms/ml) was 27%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094444      PMCID: PMC180546          DOI: 10.1128/AAC.30.2.330

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 2.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

3.  In vitro activity of CI-934, a quinolone carboxylic acid active against gram-positive and -negative bacteria.

Authors:  M A Cohen; T J Griffin; P A Bien; C L Heifetz; J M Domagala
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

4.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

  4 in total
  29 in total

1.  Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.

Authors:  M J Wolfhagen; A I Hoepelman; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

2.  Renal handling of fleroxacin in rabbits, dogs, and humans.

Authors:  K Shiba; A Saito; J Shimada; S Hori; M Kaji; T Miyahara; H Kusajima; S Kaneko; S Saito; T Ooie
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

3.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

Authors:  B G Reigner; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.

Authors:  R Wise; B Kirkpatrick; J Ashby; D J Griggs
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

5.  In vitro susceptibility of Neisseria gonorrhoeae to RO 23-6240 and ciprofloxacin.

Authors:  S S Kaukoranta-Tolvanen; O V Renkonen
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

6.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

7.  Comparative in vitro activity of cefetamet and fleroxacin against anaerobic bacteria.

Authors:  J Wüst; U Hardegger
Journal:  Eur J Clin Microbiol       Date:  1987-12       Impact factor: 3.267

8.  Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.

Authors:  A Pefanis; C Thauvin-Eliopoulos; J Holden; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; R S Matthews
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.